Pfizer’s antiviral tablet Paxlovid gets FDA approval to treat COVID-19
Category: #headlines  By Pranali Mehta  Date: 2021-12-24
  • share
  • Twitter
  • Facebook
  • LinkedIn
Pfizer’s antiviral tablet Paxlovid gets FDA approval to treat COVID-19

The U.S. Food and Drug Administration (FDA) has reportedly approved the first antiviral drug Paxlovid, which is developed by Pfizer to treat COVID-19, providing doctors with another tool to combat the virus and reduce the hospitalization rates.

Paxlovid has been approved for people aged 12 and above, especially for those who are at a high risk of becoming critically unwell if infected by Coronavirus. The pill is claimed to reduce hospitalization and death rates among high-risk patients by at least 89% when given within three days after the onset of symptoms.

The course consists of 30 pills which are to be taken at home for five days. It must be taken within a few days of the onset of symptoms, which could be relatively difficult in the United States since many people are still finding it difficult to acquire a COVID-19 test, receive a result, and see a doctor for a prescription within that time frame.

{This long-awaited achievement comes as the number of illnesses, hospitalizations, and deaths in the United States continue to rise, with health experts warning that a wave of new infections driven by the Omicron variant might soon overwhelm hospitals.

FDA has also approved Merck’s COVID-19 antiviral drug called Molnupiravir, which appears to be less successful than Paxlovid. A clinical trial indicated that Merck’s drug only reduces the chance of hospitalization and death by 30%, further compelling France to cancel its Molnupiravir order.

Monoclonal antibody treatments have been a common treatment for COVID-19 patients but are expensive and difficult to use than pills that will necessitate an infusion. But experts believe that pills could tend to be effective against the Omicron variant.

Speaking of which, the Omicron variant appears to be resistant to most monoclonal antibodies meanwhile Paxlovid presents a speedier technique to treat early COVID-19 infections and will be available in restricted quantities at first.

The Biden administration also reportedly intends to have 250,000 Pfizer tablets ready by the end of January.

Source credits-

https://www.theverge.com/2021/12/22/22810371/pfizer-merck-paxlovid-covid-antiviral-fda-authorization-omicron

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta

Pranali Mehta    

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

Petrofac collabs with Hitachi over offshore joint grid integration
Petrofac collabs with Hitachi over offshore joint grid integration
By Pranali Mehta

Petrofac, an international energy services company, and Hitachi Energy have recently collaborated to provide a joint grid integration and linked infrastructure for supporting the fast-growing offshore wind market. As per sources, this collaboratio...

Street Lighting Control System Market Size, Share to Generate Lucrative Revenues By 2028
Street Lighting Control System Market Size, Share to Generate Lucrative Revenues By 2028
By Pranali Mehta

The research report on Street Lighting Control System market Added by Market Study Report proposes a comprehensive study on the recent industry trends. In addition, the report presents a detailed abstract of the growth statistics, revenue estimation,...

Medical Crowdfunding Platform Market Size, Share to Witness Notable Hike Over 2022-2028
Medical Crowdfunding Platform Market Size, Share to Witness Notable Hike Over 2022-2028
By Pranali Mehta

The latest report on ' Medical Crowdfunding Platform market' Added by Market Study Report provides a concise analysis of the industry size, revenue forecast and regional spectrum of this business. The report further illustrates the major challenges a...